Welcome to our dedicated page for REED'S SEC filings (Ticker: REED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Reed’s, Inc. filings document the regulatory record for a Delaware branded beverage company whose common stock trades on NYSE American. Recent disclosures cover annual meeting and proxy matters, stockholder proposal and director nomination procedures, board and officer changes, executive compensation arrangements, and amendments to bylaws following the exchange listing.
Form 8-K reports also furnish operating and financial results and describe material corporate events such as leadership transitions and governance updates. Proxy materials address stockholder voting mechanics, director-election matters and corporate governance provisions for the company’s public-company structure.
Reed’s, Inc. has received a NYSE American notice that it is out of compliance with continued listing standards because it reported a stockholders’ deficit of $(1.5) million and losses from continuing operations and/or net losses in its five most recent fiscal years ended December 31, 2025. The exchange requires stockholders’ equity of at least $2.0 million under Section 1003(a)(i) of the NYSE American Company Guide, and Reed’s does not qualify for any market-capitalization-based exemption.
NYSE American has accepted Reed’s previously submitted plan to regain compliance, and the company will undergo periodic, including quarterly, reviews through November 29, 2027. Reed’s shares will continue to trade on NYSE American under the symbol REED with a “.BC” suffix indicating below-compliance status, and there is a stated possibility of delisting proceedings if the company fails to make sufficient progress or regain compliance by the deadline.
Reed’s, Inc. reported sharply lower sales and continued losses for the quarter and six months ended June 30, 2026, while showing some improvement in quarterly margins. Net sales were $7.5 million for the quarter and $14.6 million year‑to‑date, down 21% and 25% from 2025, driven by volume declines with recurring national customers and selective product liquidation.
Quarterly gross margin improved to 24% of net sales from 8% a year earlier, helped by lower inventory write‑offs and reduced delivery costs per case, though year‑to‑date gross margin slipped to 17% from 22%. Reed’s still posted a quarterly net loss of $4.3 million and a six‑month net loss of $10.7 million, with EBITDA remaining negative.
Liquidity is strained: as of June 30, 2026 cash was $2.4 million against a $9.25 million Senior Secured Loan maturing September 30, 2026, no remaining loan availability, and a stockholders’ deficit of $1.5 million. Management disclosed that these factors raise substantial doubt about the company’s ability to continue as a going concern and also highlighted the NYSE American notice that Reed’s is below certain stockholders’ equity listing standards.
Reed’s, Inc. reported second-quarter 2026 net sales of $7.5 million, down from $9.5 million a year earlier, mainly due to lower volumes with recurring national customers. Despite the sales decline, gross profit rose to $1.8 million and gross margin improved to 24% from 8%, helped by sharply lower inventory write-offs.
Operating expenses declined, with delivery and handling expense down to $1.1 million and selling, general and administrative expense at $4.7 million. Net loss narrowed to $4.3 million, or $(0.36) per share, compared with $6.0 million, or $(0.78) per share; EBITDA loss improved to $(4.0) million from $(5.7) million. Management highlights sequential gains in sales, gross margin and cost controls and continues corrective actions, including regaining retail shelf space and improving working capital.
Liquidity remains a key focus. Cash used in operations for the first half improved to $8.0 million from $10.4 million, but cash fell to $2.4 million at June 30, 2026 from $10.4 million at year-end 2025, with total debt at $9.2 million and stockholders’ equity in a $1.5 million deficit. The company is evaluating financing alternatives to support its business and aims for continued gross margin expansion and progress toward profitable growth.
Reed’s, Inc. reported results from its 2026 annual stockholder meeting. Stockholders approved the Reed’s, Inc. 2026 Equity Incentive Plan, which became effective immediately upon approval. They also elected five directors to serve until the 2027 annual meeting.
Stockholders ratified Weinberg & Company P.A. as independent registered public accounting firm for the fiscal year ending December 31, 2026. They approved the compensation of named executive officers in an advisory vote and chose a three-year frequency for future advisory votes on executive compensation, which the Board adopted.
Era Regenerative Medicine Ltd., D&D Source of Life Holding Ltd., Deng Shufen and Dai Siqi filed Amendment No. 5 to their Schedule 13D on Reed's, Inc. common stock. They report beneficial ownership of 6,363,069 shares, representing about 53.5% of Reed's outstanding common stock.
This total includes 5,956,737 shares held directly by D&D, 38,685 shares issuable from currently exercisable warrants, and 367,647 shares held directly by ERM. An additional 1,250,000 warrants held by D&D are blocked from exercise by a 4.99%–9.99% ownership cap and are not counted as beneficially owned.
D&D has pledged 4,000,000 shares under one pledge agreement and 1,950,000 shares under another as collateral for obligations of third parties in transactions unrelated to Reed's. Before any default and notice of exclusive control, D&D retains voting and dividend rights over the pledged shares, shared with ERM as described.
Reed’s, Inc. reported that NYSE American notified the company on May 29, 2026 that it no longer meets continued listing standards because its stockholders’ equity was $2.7 million as of March 31, 2026, below the required $4.0 million and $6.0 million thresholds tied to multi-year net losses.
Reed’s must submit a plan by June 28, 2026 describing how it will regain compliance by November 29, 2027, an eighteen‑month cure period. Its common stock will remain listed on NYSE American during this time but will trade under the symbol “REED.BC” to reflect its below‑compliance status. The company states that the notice does not change its day‑to‑day operations or SEC reporting and that it intends to submit a plan, though there is no assurance it will restore compliance or avoid potential delisting.
Reed’s, Inc. reported a much weaker first quarter of 2026. Net sales fell to $7,142 thousand from $10,029 thousand a year earlier, a 29% decline driven by lower volumes and heavier promotional discounts. Gross margin shrank to 10% of net sales from 34%, hurt by $738 thousand of inventory write-offs tied to product portfolio changes and higher cost per case.
Operating expenses rose to $6,912 thousand, up 34%, with general and administrative costs more than doubling to support an Asia-Pacific growth initiative. The company’s net loss widened to $6,464 thousand, or $0.55 per share, versus a loss of $2,031 thousand, or $0.27 per share. EBITDA was a loss of $6,218 thousand.
Cash decreased to $4,580 thousand as of March 31, 2026, from $10,424 thousand at year-end 2025, mainly due to operating losses and working capital needs. Reed’s has a fully drawn senior secured loan of $9,250 thousand and no remaining availability, but management believes existing cash, operations, and committed financing can fund the approved operating plan for at least twelve months.
Reed’s, Inc. reported significantly weaker first-quarter 2026 results, with net sales of $7.1 million versus $10.0 million a year earlier. Gross profit fell to $0.7 million and gross margin compressed to 10% from 34%, reflecting discontinued and slow-moving inventory write-offs and higher costs.
Operating expenses rose sharply, as selling, general and administrative costs increased to $5.8 million from $3.5 million, contributing to a wider net loss of $6.5 million or $(0.55) per share, compared with a net loss of $2.0 million or $(0.27) per share. EBITDA was $(6.2) million versus $(1.7) million in the prior-year quarter.
Cash used in operations was $5.8 million, leaving cash at $4.6 million as of March 31, 2026, down from $10.4 million at year-end, while total debt remained about $9.2 million. Management detailed numerous corrective actions, including portfolio rationalization, cost reductions, expanded sales partnerships, and a new chief operating officer appointment, and stated that first-quarter performance is not viewed as indicative of the rest of 2026.
REED'S, INC. filed an initial Form 3 for Chief Operating Officer Damian Francis Warshall. This filing reports his status as an insider but shows no buy, sell, or other share transactions and no derivative holdings, serving purely as a baseline disclosure of his position.